In preclinical models, we also revealed that Glrx knockdown reduced lung colonization of TSC2‐deficient cells and suppressed tumour growth, supporting that Glrx was a critical regulator of the survival of TSC2‐deficient cells in vivo. The gene discussed is GLRX; the disease is neoplasm.